US Patent

US11103517 — Pharmaceutical compositions for minocycline

Formulation · Assigned to Dr Reddys Laboratories Ltd · Expires 2036-04-07 · 10y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of orally administering a once-daily minocycline tablet that is substantially free of lactose.

USPTO Abstract

The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: US11103517
Jurisdiction: US
Classification: Formulation
Expires: 2036-04-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Dr Reddys Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.